News | Brachytherapy Systems | January 04, 2019

Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer

Patient-reported outcomes show smaller late toxicity profile for brachytherapy with similar progression-free survival to brachytherapy plus external beam therapy

Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer

January 4, 2018 — Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity profile for external beam radiotherapy and brachytherapy (EBT+ B) versus transperineal interstitial permanent brachytherapy (B) alone in men with intermediate-risk prostate cancer. The results from the NRG Oncology trial RTOG 0232, presented at the 2018 American Society for Radiation Oncology (ASTRO) annual meeting, did show similarities in progression-free survival.

NRG-RTOG 0232 evaluated the differences between progression-free survival and patient-reported outcomes on two separate treatment arms. The first arm was treated with combined partial pelvis EBT+B, whereas the second was treated with B alone. Men with prostate carcinoma were randomly assigned to receive treatment on one of the two arms. Researchers measured changes from baseline to 4 and 24 months using expanded prostate index composite (EPIC) and assessed three prostate cancer-specific PRO domains that included bowel, urinary and sexual.

“Although progression-free survival was similar on both treatment arms, the addition of external beam therapy yielded a higher percentage of clinician-reported late grade 3 or greater toxicities. The patient-reported data confirms that brachytherapy alone is the superior treatment for this for men with intermediate risk prostate cancer, with less patient-reported side effects. Brachytherapy alone would also be the most cost efficient treatment option for patients,” stated Deborah W. Bruner, RN, Ph.D., FANN, the abstract’s lead author and the Emory University Senior Vice President for Research.

At 24 months following their treatment, researchers found that the men on the EBT + B arm reported poorer urinary, bowel and sexual PROs and much greater toxicities than the B alone arm. Late grade 3 or greater clinical reported toxicities were 13 percent for the EBT+B arm and 7 percent for the B alone arm. Late grade 3 or greater bladder/genitourinary toxicity, the major symptom of concern, was underreported by clinician-report compared to patient-report. Clinicians reported late grade 3 or greater bladder/genitourinary toxicities of 8 percent for the EBT+B arm and 3 percent for the B alone arm compared to patient reports of 34 percent bladder/genitourinary toxicities for the EBT+B arm and 23 percent for the B alone arm. This further demonstrated the critical role patient-reported outcomes play in assessing treatment efficacy and clinically relevant symptoms.

For more information: www.astro.org

Reference

Bruner D.W., Moughan J., Prestidge B.R., et al. Patient Reported Outcomes of NRG Oncology/RTOG 0232: A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone in Intermediate Risk Prostate Cancer. Abstract presented at the annual meeting of the American Society for Radiation Oncology (ASTRO).

Related Content

 Prostate cancer MRI
News | Clinical Trials | November 15, 2019
November 15, 2019 — Theragnostics, which is developing innovative radiopharm
Members of Congress from both sides of the aisle issued a series of oversight letters to the Centers for Medicare and Medicaid Services (CMS) in recent months to urge the Agency to adjust its proposed radiation oncology advanced alternative payment model (RO Model)

Image by whitfieldink from Pixabay

News | Radiation Oncology | November 13, 2019
November 13, 2019 — Members of Congress from both sides of the aisle issued a series of oversight letters to the...
An image on Brigham and Women's Hospital's 7T MRI system

An image on Brigham and Women's Hospital's 7T MRI system. Image courtesy of Brigham and Women's Hospital

News | Magnetic Resonance Imaging (MRI) | November 13, 2019
November 13, 2019 — Increased immune system activity along the surface of the brain, or meningeal inflammation, may b
Image by Dr. Manuel González Reyes from Pixabay

Image by Dr. Manuel González Reyes from Pixabay 

News | SPECT Imaging | November 08, 2019
November 8, 2019 — Using ground-breaking technology, researchers at the...
This chest X-ray of a patient being treated for e-cigarette or vaping-associated lung injury shows lung opacities, densities and whitish cloud-like areas which are typically seen with unusual pneumonias, fluid in lungs or lung inflammation. Image courtesy of Intermountain Healthcare

This chest X-ray of a patient being treated for e-cigarette or vaping-associated lung injury shows lung opacities, densities and whitish cloud-like areas which are typically seen with unusual pneumonias, fluid in lungs or lung inflammation. Image courtesy of Intermountain Healthcare

News | Clinical Trials | November 08, 2019
November 8, 2019 — As the outbreak of lung injuries and deaths associated with e-cigarettes, or...
Unlike other technologies for imaging the placenta, pCASL MRI can distinguish maternal blood from fetal blood

Image courtesy of Pixabay

News | Clinical Trials | November 07, 2019
November 7, 2019 — A new imaging technique to track
Liver cancer tumor scanning using an MRI
News | Proton Therapy | November 04, 2019
November 4, 2019 – Two new studies support and inform the use of proton radiation therapy to treat patients with hepa
Attendees of ASTRO 2019 walked the halls of McCormick Place in Chicago, Ill.

Attendees of ASTRO 2019 walked the halls of McCormick Place in Chicago, Ill.

Feature | ASTRO | October 30, 2019 | By Greg Freiherr
At the American Society for Radiation Oncology’s (ASTRO) 2019 a